LeMaitre Vascular Inc (LMAT)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $1.79B
Last updated: Nov 17, 2026 at 11:06 AM ET
LeMaitre Vascular Inc (LMAT) Earnings: Report Dates and Results
LeMaitre Vascular (LMAT) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, LeMaitre Vascular reported EPS of $0.65, below the $0.69 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LMAT has an expected report date of Feb 23, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 8.8% above the $0.68 reported for the quarter ended Dec 31, 2025.
LMAT Earnings Call
The latest LMAT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, LMAT beat 21, missed 13 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $67.97M, up 11.3% from $61.05M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.65 | $0.69 | $0.68 - $0.69 | -5.80% | Miss | -13.3% | 8 | 0 up, 8 down | Nov 4, 2026 | $67.97M |
| Jun 30, 2026 | $0.74 | $0.81 | $0.79 - $0.82 | -8.64% | Miss | +23.3% | 9 | 7 up, 0 down | Aug 4, 2026 | $70.38M |
| Mar 31, 2026 | $0.68 | $0.66 | $0.64 - $0.68 | +3.03% | Beat | +41.7% | 9 | 6 up, 0 down | May 5, 2026 | $66.55M |
| Dec 31, 2025 | $0.68 | $0.66 | $0.63 - $0.68 | +3.03% | Beat | +38.8% | 10 | 1 up, 0 down | Feb 25, 2026 | $64.45M |
| Sep 30, 2025 | $0.75 | $0.56 | $0.54 - $0.58 | +33.93% | Beat | +53.1% | 8 | 0 up, 0 down | Nov 6, 2025 | $61.05M |
| Jun 30, 2025 | $0.60 | $0.57 | $0.55 - $0.58 | +5.26% | Beat | +15.4% | 9 | 1 up, 4 down | Aug 5, 2025 | $64.23M |
| Mar 31, 2025 | $0.48 | $0.50 | $0.48 - $0.52 | -4.00% | Miss | +9.1% | 9 | 1 up, 1 down | May 1, 2025 | $59.87M |
| Dec 31, 2024 | $0.49 | $0.49 | $0.47 - $0.52 | 0.00% | In line | +28.9% | 9 | 5 up, 0 down | Feb 27, 2025 | $55.72M |
| Sep 30, 2024 | $0.49 | $0.43 | $0.42 - $0.45 | +13.95% | Beat | +48.5% | 10 | 0 up, 0 down | Oct 31, 2024 | $54.82M |
| Jun 30, 2024 | $0.52 | $0.47 | $0.45 - $0.49 | +10.64% | Beat | +40.5% | 9 | 0 up, 0 down | Aug 1, 2024 | $55.85M |
| Mar 31, 2024 | $0.44 | $0.39 | $0.37 - $0.40 | +12.82% | Beat | +63.0% | 8 | 0 up, 0 down | May 2, 2024 | $53.48M |
| Dec 31, 2023 | $0.38 | $0.36 | $0.34 - $0.37 | +5.56% | Beat | +52.0% | 9 | 1 up, 0 down | Feb 27, 2024 | $48.88M |
| Sep 30, 2023 | $0.33 | $0.30 | $0.28 - $0.32 | +10.00% | Beat | +32.0% | 6 | 0 up, 0 down | Nov 1, 2023 | $47.41M |
| Jun 30, 2023 | $0.37 | $0.32 | $0.30 - $0.34 | +15.63% | Beat | +27.6% | 7 | 0 up, 0 down | Aug 1, 2023 | $50.12M |
| Mar 31, 2023 | $0.27 | $0.25 | $0.24 - $0.26 | +8.00% | Beat | 0.0% | 7 | 0 up, 0 down | May 2, 2023 | $47.08M |
| Dec 31, 2022 | $0.25 | $0.26 | $0.24 - $0.29 | -3.85% | Miss | -10.7% | 7 | 0 up, 0 down | Feb 23, 2023 | $40.95M |
| Sep 30, 2022 | $0.25 | $0.28 | $0.27 - $0.31 | -10.71% | Miss | -16.7% | 8 | 0 up, 0 down | Oct 27, 2022 | $39.03M |
| Jun 30, 2022 | $0.29 | $0.30 | $0.22 - $0.36 | -3.33% | Miss | -27.5% | 8 | 1 up, 0 down | Jul 28, 2022 | $42.11M |
| Mar 31, 2022 | $0.27 | $0.28 | $0.26 - $0.28 | -3.57% | Miss | -3.6% | 7 | 0 up, 0 down | Apr 28, 2022 | $39.56M |
| Dec 31, 2021 | $0.28 | $0.31 | $0.29 - $0.32 | -9.68% | Miss | -17.6% | 8 | 0 up, 1 down | Feb 24, 2022 | $39.50M |
| Sep 30, 2021 | $0.30 | $0.33 | $0.31 - $0.35 | -9.09% | Miss | -14.3% | 8 | N/A | Oct 28, 2021 | $38.37M |
| Jun 30, 2021 | $0.40 | $0.36 | $0.29 - $0.40 | +11.11% | Beat | +90.5% | 6 | N/A | Jul 29, 2021 | $40.67M |
| Mar 31, 2021 | $0.28 | $0.27 | $0.24 - $0.29 | +3.70% | Beat | +75.0% | 6 | N/A | Apr 29, 2021 | $35.88M |
| Dec 31, 2020 | $0.34 | $0.29 | $0.25 - $0.32 | +17.24% | Beat | +47.8% | 6 | N/A | Feb 25, 2021 | $37.55M |
| Sep 30, 2020 | $0.35 | $0.19 | $0.17 - $0.22 | +84.21% | Beat | +40.0% | 5 | N/A | Oct 29, 2020 | $36.42M |
| Jun 30, 2020 | $0.21 | $0.01 | -$0.09 - $0.13 | N/A | N/A | -8.7% | 6 | N/A | Jul 23, 2020 | $24.85M |
| Mar 31, 2020 | $0.16 | $0.16 | $0.12 - $0.17 | 0.00% | In line | -5.9% | 6 | N/A | Apr 30, 2020 | $30.55M |
| Dec 31, 2019 | $0.23 | $0.23 | $0.22 - $0.23 | 0.00% | In line | +21.1% | 7 | N/A | Feb 6, 2020 | $30.17M |
| Sep 30, 2019 | $0.25 | $0.21 | $0.20 - $0.22 | +19.05% | Beat | +19.0% | 7 | N/A | Oct 23, 2019 | $29.10M |
| Jun 30, 2019 | $0.23 | $0.21 | $0.20 - $0.22 | +9.52% | Beat | +9.5% | 7 | N/A | Jul 24, 2019 | $29.48M |
| Mar 31, 2019 | $0.17 | $0.19 | $0.19 - $0.20 | -10.53% | Miss | -10.5% | 7 | N/A | May 1, 2019 | $28.48M |
| Dec 31, 2018 | $0.19 | $0.19 | $0.18 - $0.24 | 0.00% | In line | -9.5% | 6 | N/A | Feb 19, 2019 | $28.39M |
| Sep 30, 2018 | $0.21 | $0.21 | $0.20 - $0.22 | 0.00% | In line | -16.0% | 7 | N/A | Oct 4, 2018 | $24.16M |
| Jun 30, 2018 | $0.21 | $0.42 | $0.41 - $0.43 | -50.00% | Miss | -8.7% | 8 | N/A | Jul 26, 2018 | $27.02M |
| Mar 31, 2018 | $0.19 | $0.21 | $0.20 - $0.23 | -9.52% | Miss | +18.8% | 6 | N/A | Apr 25, 2018 | $25.99M |
| Dec 31, 2017 | $0.21 | $0.20 | $0.19 - $0.21 | +5.00% | Beat | +61.5% | 6 | N/A | Feb 21, 2018 | $26.15M |
| Sep 30, 2017 | $0.25 | $0.20 | $0.20 - $0.21 | +25.00% | Beat | +47.1% | 8 | N/A | Oct 26, 2017 | $24.82M |
| Jun 30, 2017 | $0.23 | $0.17 | $0.17 - $0.17 | +35.29% | Beat | +64.3% | 8 | N/A | Jul 27, 2017 | $25.75M |
| Mar 31, 2017 | $0.16 | $0.13 | N/A | +23.08% | Beat | +45.5% | N/A | N/A | Apr 26, 2017 | $24.14M |
| Dec 31, 2016 | $0.13 | $0.15 | N/A | -13.33% | Miss | 0.0% | N/A | N/A | Feb 21, 2017 | $23.29M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.51, up 29.4% from the year before. It was $0.55 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.51 | +29.4% |
| Dec 31, 2024 | $1.94 | +43.7% |
| Dec 31, 2023 | $1.35 | +27.4% |
| Dec 31, 2022 | $1.06 | -15.9% |
| Dec 31, 2021 | $1.26 | +18.9% |
| Dec 31, 2020 | $1.06 | +20.5% |
| Dec 31, 2019 | $0.88 | +10.0% |
| Dec 31, 2018 | $0.80 | -5.9% |
| Dec 31, 2017 | $0.85 | +54.5% |
| Dec 31, 2016 | $0.55 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,400 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,419 | 10 | |
| 2026Q2 | Jun 30, 2026 | 3,941 | 10 | |
| 2026Q1 | Mar 31, 2026 | 4,231 | 13 | |
| 2025Q4 | Dec 31, 2025 | 5,894 | 12 | |
| 2025Q3 | Sep 30, 2025 | 6,780 | 13 | |
| 2025Q2 | Jun 30, 2025 | 5,051 | 14 | |
| 2025Q1 | Mar 31, 2025 | 6,800 | 10 | |
| 2024Q4 | Dec 31, 2024 | 4,132 | 13 |
2026Q3 Earnings Call
Opening remarks
Dorian LeBlanc CFO Good afternoon, and thank you for joining us on our Q3 2026 conference call. With me on today's call is our CEO, George LeMaitre. Before we begin, I will read our safe harbor statement. Today, we will be making some forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties. Wherever possible, we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast, might, and similar expressions. Our forward-looking statements are based on our estimates and assumptions as of today, November 4, 2026, and should not be relied upon as representing our estimates or views on any subsequent date. Please refer to the cautionary statement regarding forward-looking information and the risk factors in our most recent 10-K and subsequent SEC filings, including disclosure of the factors that could cause results to differ materially from those expressed or implied. During this call, we will discuss non-GAAP financial measures such as organic sales growth. A reconciliation of GAAP to non-GAAP measures discussed in this call is contained in the associated press release and in the investor relations section of our website, www.lemaitre.com. I will now turn the call over to George LeMaitre.
George LeMaitre CEO Thanks, Dorian. Sales grew 12% organically in Q3, 7% from price and 5% from units. Grafts grew 20% and shunts 14%. Biologics continued to outpace the rest of our portfolio, as Artegraft was up 18% and RestoreFlow allografts were up 34%. Geographically, EMEA sales increased 18%, the Americas 9%, and APAC 5%. On October 14, we acquired several devices from B. Braun: polyester and silver-coated vascular grafts, valve cutters, and vein strippers. This is our third polyester graft acquisition since 2007, and we look set to become number three in worldwide share, excluding Japan. We have always wanted to offer silver-coated vascular grafts, as they are designed to resist infection. The acquired portfolio posted 2025 sales of $9.4 million, all outside North America. Sixty-five percent of sales were in Europe, including 21% in Germany, our second-largest market. While the sales transition will take about two years, this acquisition is right out of our playbook. We acquire niche vascular and cardiac products and grow them through our global sales channel. As for Artegraft, we are investing in the product in several ways. Number one, more international approvals. Number two, increased lengths for leg bypasses. Number three, building out our commercial infrastructure and sales force. Q3 international Artegraft sales were $3 million, and we continue to expect full-year sales of more than $11 million. In Q3, we received approvals in Brazil and Saudi Arabia, bringing us to 60 countries.
Frequently Asked Questions About LMAT
When is LeMaitre Vascular's next earnings date?
LeMaitre Vascular's next earnings report is expected for Feb 23, 2027.
Did LMAT beat earnings estimates last quarter?
No. LeMaitre Vascular reported EPS of $0.65 for the quarter ended Sep 30, 2026, below the $0.69 estimate by 5.80%.
What EPS do analysts expect from LMAT next quarter?
The consensus EPS estimate for LeMaitre Vascular for the quarter ending Dec 31, 2026 is $0.74 from 10 analysts, with estimates from $0.71 to $0.78.
How often does LMAT beat earnings estimates?
LeMaitre Vascular beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +3.35%.
LMAT pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts